Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Literature DB >> 1695259

An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

S R Burrows¹, I S Misko, T B Sculley, C Schmidt, D J Moss.

Abstract

In this report we describe a cytotoxic T-cell epitope in the Epstein-Barr virus nuclear antigen EBNA 6. This epitope is present on both A- and B-type transformants.

Entities: Species

Mesh：

Substances：

Year: 1990 PMID： 1695259 PMCID： PMC249694

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

18 in total

1. T-cell antigenic sites tend to be amphipathic structures.

Authors: C DeLisi; J A Berzofsky
Journal: Proc Natl Acad Sci U S A Date: 1985-10 Impact factor: 11.205

2. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors: R A Houghten
Journal: Proc Natl Acad Sci U S A Date: 1985-08 Impact factor: 11.205

3. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.

Authors: T B Sculley; A Apolloni; R Stumm; D J Moss; N Mueller-Lantczh; I S Misko; D A Cooper
Journal: Virology Date: 1989-08 Impact factor: 3.616

4. Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins.

Authors: M Rowe; L S Young; K Cadwallader; L Petti; E Kieff; A B Rickinson
Journal: J Virol Date: 1989-03 Impact factor: 5.103

Review 5. Antigen recognition by class I-restricted T lymphocytes.

Authors: A Townsend; H Bodmer
Journal: Annu Rev Immunol Date: 1989 Impact factor: 28.527

6. A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes.

Authors: L Petti; E Kieff
Journal: J Virol Date: 1988-06 Impact factor: 5.103

7. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors: D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal: Nature Date: 1988-02-25 Impact factor: 49.962

8. Geographical prevalence of two types of Epstein-Barr virus.

Authors: U Zimber; H K Adldinger; G M Lenoir; M Vuillaume; M V Knebel-Doeberitz; G Laux; C Desgranges; P Wittmann; U K Freese; U Schneider
Journal: Virology Date: 1986-10-15 Impact factor: 3.616

9. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors: G Miller; M Lipman
Journal: Proc Natl Acad Sci U S A Date: 1973-01 Impact factor: 11.205

10. A sequence pattern common to T cell epitopes.

Authors: J B Rothbard; W R Taylor
Journal: EMBO J Date: 1988-01 Impact factor: 11.598

31 in total

Review 1. The immunology of Epstein-Barr virus infection.

Authors: D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal: Philos Trans R Soc Lond B Biol Sci Date: 2001-04-29 Impact factor: 6.237

2. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing.

Authors: S R Burrows; A Suhrbier; R Khanna; D J Moss
Journal: Immunology Date: 1992-05 Impact factor: 7.397

3. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors: R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal: Proc Natl Acad Sci U S A Date: 1992-07-01 Impact factor: 11.205

4. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.

Authors: J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff
Journal: Proc Natl Acad Sci U S A Date: 1991-07-15 Impact factor: 11.205

5. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.

Authors: C Schmidt; S R Burrows; T B Sculley; D J Moss; I S Misko
Journal: Proc Natl Acad Sci U S A Date: 1991-11-01 Impact factor: 11.205

6. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines.

Authors: R Khanna; S R Burrows; A Neisig; J Neefjes; D J Moss; S L Silins
Journal: J Virol Date: 1997-10 Impact factor: 5.103

7. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors: M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal: J Virol Date: 1992-01 Impact factor: 5.103

8. Prediction of an HLA-B44 binding motif by the alignment of known epitopes and molecular modeling of the antigen binding cleft.

Authors: C J Thorpe; P J Travers
Journal: Immunogenetics Date: 1994 Impact factor: 2.846

9. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors: S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal: J Virol Date: 1998-11 Impact factor: 5.103

10. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors: S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal: J Virol Date: 1996-04 Impact factor: 5.103